

Giovanni Cammarota

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4132145/publications.pdf>

Version: 2024-02-01

362
papers

14,725
citations

20797

60
h-index

25770

108
g-index

366
all docs

366
docs citations

366
times ranked

14736
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009, 49, 1877-1887.	3.6	1,138
2	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	6.1	793
3	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 835-843.	1.9	467
4	Fecal Microbiota Transplantation for the Treatment of <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 693-702.	1.1	375
5	Association of Virulent <i>Helicobacter pylori</i> Strains With Ischemic Heart Disease. <i>Circulation</i> , 1998, 97, 1675-1679.	1.6	299
6	Effect of different probiotic preparations on anti- <i>Helicobacter pylori</i> therapy-related side effects: a parallel group, triple blind, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2002, 97, 2744-2749.	0.2	299
7	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	6.1	290
8	Identification of a CD4 binding site on the $\beta 2$ domain of HLA-DR molecules. <i>Nature</i> , 1992, 356, 799-801.	13.7	277
9	The effect of oral administration of <i>Lactobacillus GG</i> on antibiotic-associated gastrointestinal side-effects during <i>Helicobacter pylori</i> eradication therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 163-169.	1.9	245
10	Probiotics in prevention and treatment of obesity: a critical view. <i>Nutrition and Metabolism</i> , 2016, 13, 14.	1.3	235
11	A lyophilized and inactivated culture of <i>Lactobacillus acidophilus</i> increases <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1625-1629.	1.9	204
12	Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1391-1395.	1.9	174
13	Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Alcohol and Alcoholism</i> , 2011, 46, 312-317.	0.9	173
14	Gut microbiome, big data and machine learning to promote precision medicine for cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 635-648.	8.2	172
15	Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1157-1160.	1.9	161
16	Management and treatment of lactose malabsorption. <i>World Journal of Gastroenterology</i> , 2006, 12, 187.	1.4	159
17	<i>Bacillus clausii</i> therapy to reduce side-effects of anti- <i>Helicobacter pylori</i> treatment: randomized, double-blind, placebo controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1181-1188.	1.9	156
18	Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	156

#	ARTICLE	IF	CITATIONS
19	Effect of <i>Lactobacillus GG</i> Supplementation on Antibiotic-Associated Gastrointestinal Side Effects during <i>Helicobacter pylori</i> Eradication Therapy: A Pilot Study. <i>Digestion</i> , 2001, 63, 1-7.	1.2	155
20	The role of diet on gut microbiota composition. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 4742-4749.	0.5	149
21	Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1339-1343.	1.9	146
22	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. <i>Digestive Diseases</i> , 2018, 36, 56-65.	0.8	146
23	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 240-248.	1.9	144
24	Role and mechanisms of action of <i>Escherichia coli</i> Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. <i>World Journal of Gastroenterology</i> , 2016, 22, 5505.	1.4	141
25	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. <i>Gut</i> , 2015, 149, 191-212.		139
26	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1232-1244.	1.6	137
27	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. <i>British Journal of Pharmacology</i> , 2017, 174, 1426-1449.	2.7	126
28	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	1.1	123
29	Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-11.	0.7	119
30	Onset of coeliac disease during treatment with interferon for chronic hepatitis C. <i>Lancet</i> , The, 2000, 356, 1494-1495.	6.3	118
31	Systematic review: sprue-like enteropathy associated with olmesartan. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 16-23.	1.9	117
32	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory <i>Clostridium difficile</i> infection—single versus multiple infusions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 152-159.	1.9	117
33	Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 33-42.	1.9	115
34	Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 2031-2035.	0.2	112
35	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	6.1	110
36	Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4180-4184.	1.8	108

#	ARTICLE	IF	CITATIONS
37	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 430-432.	3.7	108
38	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016, 34, 269-278.	0.8	105
39	Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 31-35.	1.9	102
40	High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 789-795.	1.9	98
41	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. <i>Internal and Emergency Medicine</i> , 2014, 9, 365-373.	1.0	98
42	Levofloxacin-based triple therapy vs. quadruple therapy in second-line <i>Helicobacter pylori</i> treatment: a randomized trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 627-633.	1.9	95
43	High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 781-786.	1.9	94
44	The Role of Acid and Alkaline Reflux in Laryngeal Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2002, 112, 1861-1865.	1.1	91
45	Digestive Enzyme Supplementation in Gastrointestinal Diseases. <i>Current Drug Metabolism</i> , 2016, 17, 187-193.	0.7	87
46	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. <i>Applied and Environmental Microbiology</i> , 2016, 82, 6633-6644.	1.4	85
47	Review article: biofilm formation by <i>Helicobacter pylori</i> as a target for eradication of resistant infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 222-230.	1.9	84
48	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	5.8	82
49	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	2.0	81
50	Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant <i>Helicobacter pylori</i> : A Clinical Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 817-820.e3.	2.4	79
51	High Prevalence of Celiac Disease in Patients with Lactose Intolerance. <i>Digestion</i> , 2005, 71, 106-110.	1.2	77
52	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2014, 93, e97.	0.4	77
53	Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. <i>Current Drug Targets</i> , 2014, 15, 762-770.	1.0	74
54	Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 732-738.	0.5	72

#	ARTICLE	IF	CITATIONS
55	Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. <i>American Journal of Cardiology</i> , 2004, 94, 40-44.	0.7	71
56	Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 183.	1.8	70
57	Levofloxacin-Based Triple Therapy in First-Line Treatment for <i>Helicobacter pylori</i> Eradication. <i>American Journal of Gastroenterology</i> , 2006, 101, 1985-1990.	0.2	67
58	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021, 9, 229-247.	1.6	66
59	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. <i>Journal of Clinical Medicine</i> , 2020, 9, 1757.	1.0	65
60	Role of Dental Plaque in the Transmission of <i>Helicobacter Pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 174-177.	1.1	65
61	Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 348-351.	0.5	64
62	Levofloxacin based regimens for the eradication of <i>Helicobacter pylori</i> . <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1309-1312.	0.8	62
63	Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification. <i>Digestive Diseases</i> , 2015, 33, 68-76.	0.8	62
64	Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	1.4	62
65	<i>Bacillus clausii</i> for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2018, 10, 1074.	1.7	62
66	Moxifloxacin-based strategies for first-line treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1241-1247.	1.9	61
67	Virulent strains of <i>Helicobacter pylori</i> and vascular diseases: A meta-analysis. <i>American Heart Journal</i> , 2006, 151, 1215-1222.	1.2	60
68	Reflux Symptoms in Professional Opera Choristers. <i>Gastroenterology</i> , 2007, 132, 890-898.	0.6	60
69	Predictors of failure after single faecal microbiota transplantation in patients with recurrent <i>Clostridium difficile</i> infection: results from a 3-year, single-centre cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 337.e1-337.e3.	2.8	60
70	A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. <i>European Journal of Immunology</i> , 1995, 25, 1461-1464.	1.6	58
71	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.	1.1	58
72	Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. <i>Digestive and Liver Disease</i> , 2007, 39, 483-487.	0.4	57

#	ARTICLE	IF	CITATIONS
73	Decrease in Surgery for <i>Clostridium difficile</i> Infection After Starting a Program to Transplant Fecal Microbiota. <i>Annals of Internal Medicine</i> , 2015, 163, 487-488.	2.0	56
74	Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1003-1012.	1.9	54
75	Prevention and Treatment of Low-grade B-cell Primary Gastric Lymphoma by Anti-H. Pylori Therapy. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 118-122.	1.1	53
76	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110258.	2.5	52
77	Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. <i>Current Pharmaceutical Design</i> , 2014, 20, 4565-4569.	0.9	51
78	The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 455-466.	3.2	50
79	Combined atherogenic effects of celiac disease and type 1 diabetes mellitus. <i>Atherosclerosis</i> , 2011, 217, 531-535.	0.4	48
80	FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 1021.	1.1	48
81	<i>Helicobacter pylori</i> reinfection and rapid relapse of low-grade B-cell gastric lymphoma. <i>Lancet</i> , The, 1995, 345, 192.	6.3	47
82	Mono, dual and triple moxifloxacin-based therapies for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 527-532.	1.9	47
83	Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 223-228.	0.5	46
84	Autologous faecal microbiota transplantation for type 1 diabetes: a potential mindshift in therapeutic microbiome manipulation?. <i>Gut</i> , 2021, 70, 2-3.	6.1	45
85	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	43
86	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100181.	3.0	43
87	A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study. <i>Endoscopy</i> , 2007, 39, 46-51.	1.0	41
88	Emerging technologies in upper gastrointestinal endoscopy and celiac disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 47-56.	1.7	41
89	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 599-622.	1.4	41
90	Microscopic colitis. <i>World Journal of Gastroenterology</i> , 2012, 18, 6206.	1.4	40

#	ARTICLE	IF	CITATIONS
91	Faecal calprotectin concentrations in untreated coeliac patients. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 957-961.	0.6	39
92	Gut Virome and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1708-1712.	0.9	39
93	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 501.	1.8	39
94	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
95	Third-line rescue therapy for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2006, 12, 2313.	1.4	39
96	Increased frequency of the immunoglobulin enhancer HS1,2 allele 2 in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 1083-1087.	0.6	38
97	High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against <i>Helicobacter pylori</i> isolates from patients after failure of therapy. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 433-438.	1.1	38
98	High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic approach in diagnosing coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 61-69.	1.9	38
99	Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. <i>Digestive and Liver Disease</i> , 2013, 45, 1017-1021.	0.4	38
100	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 5205.	1.4	38
101	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	1.4	37
102	<i>Helicobacter pylori</i> Eradication and Remission of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 169-171.	1.1	36
103	Skeletal muscle wastage in Crohn's disease: A pathway shared with heart failure?. <i>International Journal of Cardiology</i> , 2008, 127, 219-227.	0.8	35
104	Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment. <i>Human Immunology</i> , 2009, 70, 430-435.	1.2	35
105	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1306-1314.	0.9	35
106	Biliary laryngopharyngeal reflux: a new pathological entity. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006, 14, 128-132.	0.8	34
107	Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer *2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1920-1924.	0.3	34
108	Insulin-dependent diabetes mellitus affects eradication rate of <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 713-716.	0.8	33

#	ARTICLE	IF	CITATIONS
109	The Water Immersion Technique is Easy to Learn for Routine Use During EGD for Duodenal Villous Evaluation. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 244-248.	1.1	33
110	Fecal Microbiota Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S80-S84.	1.1	33
111	<i>Helicobacter pylori</i> eradication using one-week low-dose lansoprazole plus amoxicillin and either clarithromycin or azithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 997-1000.	1.9	32
112	Involvement of central immunity in uncomplicated diverticular disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 108-115.	0.6	32
113	Endoscopic tools for the diagnosis and evaluation of celiac disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 8562.	1.4	32
114	CD4-Mediated Anchoring of the Seminal Antigen gp17 onto the Spermatozoon Surface. <i>Human Immunology</i> , 1997, 58, 30-41.	1.2	30
115	Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 352-357.	0.5	30
116	Nickel Free-Diet Enhances the <i>Helicobacter pylori</i> Eradication Rate: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1851-1855.	1.1	30
117	Partial nucleotide sequencing of six subtype 2c hepatitis C viruses detected in Italy. <i>Journal of Clinical Microbiology</i> , 1995, 33, 2781-2784.	1.8	30
118	Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 779-781.	0.5	29
119	Fecal Calprotectin in First-Degree Relatives of Patients with Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 132-136.	0.2	29
120	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 343-351.	1.4	29
121	Cellular Mediators of Inflammation: Tregs and T_H 17 Cells in Gastrointestinal Diseases. <i>Mediators of Inflammation</i> , 2009, 2009, 1-11.	1.4	28
122	Low-dose omeprazole plus clarithromycin and either tinidazole or amoxicillin for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 285-288.	1.9	27
123	Gastric Mucosa-Associated Lymphoid Tissue in Autoimmune Thyroid Diseases. <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 869-872.	0.6	27
124	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	0.6	27
125	Role of the Water Immersion Technique in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 571-575.	1.1	27
126	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. <i>Human Immunology</i> , 2008, 69, 837-839.	1.2	27

#	ARTICLE	IF	CITATIONS
127	Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. <i>Digestive Diseases</i> , 2018, 36, 184-193.	0.8	27
128	Link Between <i>Helicobacter pylori</i> Infection and Iron-Deficiency Anaemia in Patients with Coeliac Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 1284-1288.	0.6	26
129	Fecal Calprotectin Concentrations in Patients with Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases</i> , 2008, 26, 183-186.	0.8	26
130	Water-Immersion Technique During Standard Upper Endoscopy May Be Useful to Drive the Biopsy Sampling of Duodenal Mucosa in Children With Celiac Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 49, 411-416.	0.9	26
131	Image-Enhanced Endoscopy with I-scan Technology for the Evaluation of Duodenal Villous Patterns. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1287-1292.	1.1	26
132	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016, 48, 402-407.	0.3	26
133	<i>Helicobacter Pylori</i> Eradication Helps Resolve Pyloric and Duodenal Stenosis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 157-158.	1.1	26
134	Disappearance of Gastric Mucosa-Associated Lymphoid Tissue in Coeliac Patients after Gluten Withdrawal. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 401-405.	0.6	25
135	Association of Laryngeal Cancer With Previous Gastric Resection. <i>Annals of Surgery</i> , 2004, 240, 817-824.	2.1	25
136	Rifaximin-Based Regimens for Eradication of <i>Helicobacter pylori</i> : A Pilot Study. <i>Digestive Diseases</i> , 2006, 24, 195-200.	0.8	25
137	Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal Immunological Niche in Coeliac Disease After Gluten-Free Diet. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e28.	1.3	25
138	Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions. <i>Acta Otorhinolaryngologica Italica</i> , 2003, 23, 377-82.	0.7	25
139	Adverse Reactions to Food: Allergies and Intolerances. <i>Digestive Diseases</i> , 2008, 26, 96-103.	0.8	24
140	Celiac Disease: What's New about It?. <i>Digestive Diseases</i> , 2008, 26, 121-127.	0.8	24
141	Fecal Microbiota Transplantation Is Safe and Effective in Patients With <i>Clostridioides difficile</i> Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	2.4	24
142	Laryngeal carcinoma and laryngo-pharyngeal reflux disease. <i>Acta Otorhinolaryngologica Italica</i> , 2006, 26, 260-3.	0.7	24
143	<i>Helicobacter pylori</i> Eradication Rate and Glycemic Control in Young Patients With Type 1 Diabetes. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 38, 422-425.	0.9	23
144	Bile Acids and Total Bilirubin Detection in Saliva of Patients Submitted to Gastric Surgery and in Particular to Subtotal Billroth II Resection. <i>Annals of Surgery</i> , 2007, 245, 880-885.	2.1	23

#	ARTICLE	IF	CITATIONS
145	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. Digestive and Liver Disease, 2020, 52, 1002-1010.	0.4	23
146	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS ONE, 2017, 12, e0186575.	1.1	23
147	Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay. Journal of Antimicrobial Chemotherapy, 2006, 57, 71-78.	1.3	22
148	T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clinical and Experimental Immunology, 2009, 158, 106-114.	1.1	22
149	Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Digestive Diseases, 2016, 34, 279-285.	0.8	22
150	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nature Communications, 2021, 12, 1926.	5.8	22
151	Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterology, 2017, 63, 420-430.	0.3	22
152	Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. European Journal of Gastroenterology and Hepatology, 2006, 18, 965-967.	0.8	21
153	Celiac Disease in the 21st Century: Issues of Under-and Over-Diagnosis. International Journal of Immunopathology and Pharmacology, 2009, 22, 1-7.	1.0	21
154	Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes, 2021, 13, 1994834.	4.3	21
155	Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity. Annals of Clinical and Laboratory Science, 2010, 40, 3-9.	0.2	21
156	Coeliac disease and follicular gastritis. Lancet, The, 1996, 347, 268.	6.3	20
157	Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1259-1267.	1.4	20
158	Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year cohort study: authors' reply. Clinical Microbiology and Infection, 2017, 23, 891.	2.8	20
159	The Role of Biomarkers in Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S26-S28.	1.1	19
160	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2016, 7, e139.	1.3	19
161	Can chronic gastritis cause an increase in fecal calprotectin concentrations?. World Journal of Gastroenterology, 2010, 16, 3406.	1.4	19
162	How the gut parasitome affects human health. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210915.	1.4	19

#	ARTICLE	IF	CITATIONS
163	Post-cholecystectomy alkaline reactive gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 975-979.	0.8	18
164	High-dose Versus Low-dose Clarithromycin in 1-week Triple Therapy, Including Rabeprazole and Levofloxacin, for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 110-114.	1.1	18
165	Spectral Endoscopic Imaging. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 6-15.	1.1	18
166	Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 983-991.	1.0	18
167	Faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2018, 67, 196.2-197.	6.1	18
168	FMT for ulcerative colitis: closer to the turning point. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 266-268.	8.2	18
169	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. <i>Future Microbiology</i> , 2020, 15, 1173-1183.	1.0	18
170	<i>Helicobacter pylori</i> is an aetiological factor for ischaemic heart disease: the case against. <i>Digestive and Liver Disease</i> , 2000, 32, 65-68.	0.4	17
171	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.4	17
172	Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond <i>Clostridium difficile</i> infection: an update. <i>Drugs of Today</i> , 2018, 54, 123.	0.7	17
173	Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxicillin or tinidazole for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 73-77.	1.9	16
174	Hydrogen peroxide-related colitis (previously known as “pseudolipomatosis”): a series of cases occurring in an epidemic pattern. <i>Endoscopy</i> , 2007, 39, 916-919.	1.0	16
175	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. <i>Digestive and Liver Disease</i> , 2012, 44, 1032-1036.	0.4	16
176	Real-time diagnosis of <i>H. pylori</i> infection during endoscopy: Accuracy of an innovative tool (EndoFaster). <i>United European Gastroenterology Journal</i> , 2016, 4, 339-342.	1.6	16
177	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020, 52, 1390-1395.	0.4	16
178	The gut microbiota: its anatomy and physiology over a lifetime. <i>Minerva Gastroenterology</i> , 2017, 63, 329-336.	0.3	16
179	Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 247-250.	0.8	15
180	High-Resolution Magnifying Video Endoscopy in Primary Intestinal Lymphangiectasia: a New Role for Endoscopy?. <i>Endoscopy</i> , 2005, 37, 607-607.	1.0	15

#	ARTICLE	IF	CITATIONS
181	Quick Test: A New Test for the Diagnosis of Duodenal Hypolactasia. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1589-1592.	1.1	15
182	Letter: telmisartan associated enteropathy “ is there any class effect? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 570-570.	1.9	15
183	Accuracy of Laryngeal Examination during Upper Gastrointestinal Endoscopy for Premalignancy Screening: Prospective Study in Patients with and without Reflux Symptoms. <i>Endoscopy</i> , 2006, 38, 376-381.	1.0	14
184	Fecal Microbiota Transplantation for Severe or Fulminant <i>Clostridioides difficile</i> Infection: Systematic Review and Meta-analysis. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, e1-e11.	0.1	14
185	New insights on the role of T cells in the pathogenesis of celiac disease. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2012, 26, 171-9.	0.7	14
186	One-week therapy for <i>Helicobacter pylori</i> eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 539-543.	1.9	13
187	Prevalence of and risk factors for <i>Helicobacter pylori</i> infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 185-189.	0.8	13
188	Gastric Surgery as a Long-term Risk Factor for Malignant Lesions of the Larynx. <i>Archives of Surgery</i> , 2003, 138, 751.	2.3	13
189	High Prevalence of Hyperplastic Colonic Polyps in Acromegalic Subjects. <i>Digestive Diseases and Sciences</i> , 2004, 49, 662-666.	1.1	13
190	Classification of Malabsorption Syndromes. <i>Digestive Diseases</i> , 2008, 26, 104-111.	0.8	13
191	A Durum Wheat Variety-Based Product Is Effective in Reducing Symptoms in Patients with Non-Celiac Gluten Sensitivity: A Double-Blind Randomized Cross-Over Trial. <i>Nutrients</i> , 2019, 11, 712.	1.7	13
192	Increased <i>Faecalibacterium</i> abundance is associated with clinical improvement in patients receiving rifaximin treatment. <i>Beneficial Microbes</i> , 2020, 11, 519-525.	1.0	13
193	Is the alkaline reflux a risk factor for laryngeal lesions?. <i>American Journal of Gastroenterology</i> , 2000, 95, 2398-2398.	0.2	12
194	Worsening of Gastroesophageal Reflux Symptoms in Professional Singers During Performances. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 403-404.	1.1	12
195	Moderately Severe Acute Pancreatitis Associated With Riluzole. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 563.	1.1	12
196	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 2605.	1.0	12
197	Role of gut microbiome on immunotherapy efficacy in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	12
198	High-Resolution Magnifying Upper Endoscopy in a Patient with Patchy Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 601-604.	1.1	11

#	ARTICLE	IF	CITATIONS
217	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	1.9	9
218	A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules. <i>European Journal of Immunology</i> , 1994, 24, 991-998.	1.6	8
219	Fecal calprotectin in management of <i>Clostridium difficile</i> infection: a longitudinal study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 567-572.	0.6	8
220	Fecal microbiota transplant for <i>C. difficile</i> infection: Just say yes. <i>Anaerobe</i> , 2019, 60, 102109.	1.0	8
221	The Interaction Between Small Intestinal Bacterial Overgrowth and Warfarin Treatment. <i>American Journal of Gastroenterology</i> , 2009, 104, 2364-2365.	0.2	7
222	Tired legs—a gut diagnosis. <i>Lancet, The</i> , 2010, 376, 1798.	6.3	7
223	Ipilimumab Adjuvant Therapy in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 398-399.	13.9	7
224	Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1605-1607.	1.4	7
225	Faecal Microbiota Transplantation as Emerging Treatment in European Countries. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1050, 177-195.	0.8	7
226	Current and future targets for faecal microbiota transplantation. <i>Human Microbiome Journal</i> , 2019, 11, 100045.	3.8	7
227	Laboratory handling practice for faecal microbiota transplantation. <i>Journal of Applied Microbiology</i> , 2020, 128, 893-898.	1.4	7
228	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 923-924.	1.9	7
229	Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with <i>H. pylori</i> infection. Could the two neoplasms share a common pathogenesis?. <i>Hepato-Gastroenterology</i> , 2001, 48, 104-6.	0.5	7
230	Risk Factors, Diagnosis, and Management of <i>Clostridioides difficile</i> Infection in Patients with Inflammatory Bowel Disease. <i>Microorganisms</i> , 2022, 10, 1315.	1.6	7
231	Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against <i>Helicobacter pylori</i> infection. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2386-2389.	1.1	6
232	Is there an antigenic mimicry between arteriosclerotic lesions and <i>H. pylori</i> antigens?. <i>Clinical Biochemistry</i> , 2000, 33, 419-421.	0.8	6
233	EUS in the diagnosis of collagenous colitis. <i>Gastrointestinal Endoscopy</i> , 2001, 54, 113-115.	0.5	6
234	Relationship Between Gastric Localization of Hepatitis C Virus and Mucosa-associated Lymphoid Tissue in <i>Helicobacter pylori</i> Infection. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 1126-1132.	0.6	6

#	ARTICLE	IF	CITATIONS
235	Gluten-related recurrent peripheral facial palsy: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 667-668.	0.9	6
236	Faecal transplantation for <i>Clostridium difficile</i> infection. Three cases treated in Italy. <i>Digestive and Liver Disease</i> , 2014, 46, 475.	0.4	6
237	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. <i>Digestive and Liver Disease</i> , 2016, 48, 1043-1047.	0.4	6
238	Variation of the endoscopic pattern of low-grade gastric malt-lymphoma after <i>Helicobacter pylori</i> eradication. <i>Gastrointestinal Endoscopy</i> , 1998, 48, 231-232.	0.5	5
239	CASE REPORT: Celiac Disease and Chronic Urticaria Resolution: A Case Report. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1489-1490.	1.1	5
240	Pre- and Posttherapy Assessment of Intestinal Soluble Mediators in IBD: Where We Stand and Future Perspectives. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	1.4	5
241	Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection in a Patient with Chronic Refractory Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 367-367.	0.6	5
242	Response to: Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease". <i>Mediators of Inflammation</i> , 2018, 2018, 1-2.	1.4	5
243	Reflux symptoms in professional opera soloists. <i>Digestive and Liver Disease</i> , 2019, 51, 798-803.	0.4	5
244	Fecal calprotectin and need of multiple microbiota transplantation infusions in <i>Clostridium difficile</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1909-1915.	1.4	5
245	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	3.7	5
246	Editorial: The Role of Endoscopy in the Diagnosis and Follow-up of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 496-498.	1.1	5
247	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9727.	1.4	5
248	Abnormal synthesis of IgA in celiac disease and related disorders. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2008, 22, 99-104.	0.7	5
249	COVID-19 in celiac disease: a multicentric retrospective cohort study. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 4400-4404.	0.5	5
250	Association of <i>Helicobacter pylori</i> infection, lymphoid follicles, and lymphocytic gastritis: a risk factor for the development of primary gastric lymphoma?. <i>Gut</i> , 1996, 38, 792-792.	6.1	4
251	Regression of autoimmune thrombocytopenic purpura after <i>Helicobacter pylori</i> eradication. <i>Gastroenterology</i> , 1998, 114, A124.	0.6	4
252	<i>Helicobacter pylori</i> infection and autoimmune pathogenesis of gastric neoplasias. <i>Gut</i> , 2000, 46, 293d-293.	6.1	4

#	ARTICLE	IF	CITATIONS
253	An Attempt of Specific Desensitising Treatment with Gliadin in Celiac Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 709-714.	1.0	4
254	Letter: faecal microbiota transplantation - not a one-size-fits-all approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 119-119.	1.9	4
255	PC.01.7 RANDOMIZED CLINICAL TRIAL: SINGLE-INFUSION FMT VERSUS MULTIPLE-INFUSION FMT FOR THE TREATMENT OF SEVERE C. DIFFICILE INFECTION. <i>Digestive and Liver Disease</i> , 2018, 50, e66-e67.	0.4	4
256	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 615-615.	0.8	4
257	Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma Å Reply. <i>Gut</i> , 1997, 41, 577-577.	6.1	3
258	Oxatomide in Food Allergies. Comparative Study versus Disodium Chromoglycate. <i>International Journal of Immunopathology and Pharmacology</i> , 1998, 11, 149-154.	1.0	3
259	10 days levofloxacin-based triple therapy in second-line treatment for <i>Helicobacter pylori</i> eradication. <i>Gastroenterology</i> , 2003, 124, A359.	0.6	3
260	Preliminary Laryngeal Examination During Magnifying Upper Gastrointestinal Video Endoscopy in Two Patients with Reflux Symptoms. <i>Endoscopy</i> , 2006, 38, 287-287.	1.0	3
261	Impact evaluation of a Critical Pathway for patients with <i>Clostridium difficile</i> infection: A pre-post analysis in a Third Level Referral Center. <i>International Journal of Infectious Diseases</i> , 2019, 80, 105-110.	1.5	3
262	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. <i>Computers in Biology and Medicine</i> , 2019, 104, 335-338.	3.9	3
263	Evaluating Donor Microbiome Before Fecal Microbiota Transplantation. <i>Gastroenterology</i> , 2022, 162, 993-994.	0.6	3
264	<i>Clostridium difficile</i> : trend in an Italian Tertiary Care Hospital during fifteen years, 2002-2016. <i>Minerva Medica</i> , 2019, 110, 168-171.	0.3	3
265	Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 48-69.	2.2	3
266	Fecal Microbiome Transplantation for Recurrent <i>Clostridioides difficile</i> Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 470-476.	0.5	3
267	Regression of a primary gastric MALT lymphoma with extensive antrum lesions by <i>Helicobacter pylori</i> eradication. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1997, 29, 361-4.	0.5	3
268	<i>Helicobacter pylori</i> infection and ischaemic heart disease. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30 Suppl 3, S304-6.	0.5	3
269	Long-term omeprazole treatment and risk of gastric cancer. <i>Gastroenterology</i> , 2000, 119, 1176-1177.	0.6	2
270	Corkscrew Esophagus. <i>New England Journal of Medicine</i> , 2005, 352, 816-816.	13.9	2

#	ARTICLE	IF	CITATIONS
271	A higher diagnostic profile is possible for microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 561-561.	1.9	2
272	Free Peritoneal Gas Accumulation Caused by Pneumatosis Coli After Diagnostic Gastrointestinal Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, A18.	2.4	2
273	The combined application of advanced endoscopic imaging techniques may increase the duodenal villous morphology definition in suspected celiac disease. <i>Digestive and Liver Disease</i> , 2010, 42, 595-596.	0.4	2
274	Wheat desensitization treatment in patients with gluten sensitivity. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 320-322.	0.4	2
275	P128 Histological activity predicts clinical relapse in patients with ulcerative colitis in endoscopic remission. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S152-S152.	0.6	2
276	Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1360-1361.	0.2	2
277	<i>Clostridioides difficile</i> infection during the COVID-19 pandemic: a gut microbiota-based relationship. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 116-117.	0.3	2
278	How to define a quadruple aim framework to assess value in critical pathway of the patients with <i>Clostridioides difficile</i> infection. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 4597-4610.	0.5	2
279	Omeprazole versus ranitidine in the prevention of duodenal ulcer recurrence after eradication therapy. <i>Current Therapeutic Research</i> , 1995, 56, 568-572.	0.5	1
280	Eradication of <i>Helicobacter pylori</i> as the first step in the treatment of peptic stenosis. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 757.	0.5	1
281	What is the best azithromycin-based therapy for <i>Helicobacter pylori</i> infection?. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 111-111.	1.3	1
282	Celiac disease and autoimmune endocrine disorders. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1470-1471.	1.1	1
283	Gastric Mucosal Lesions in Celiac Patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 1364-1365.	0.2	1
284	Post-cholecystectomy Alkaline Reactive Gastritis: A randomized trial comparing sucralfate versus rabeprazole or no treatment. <i>Gastroenterology</i> , 2003, 124, A456.	0.6	1
285	A case-control study comparing methylene blue directed biopsies and random biopsies for detecting pre-cancerous lesions in the follow-up of gastric cancer patients. <i>Digestive and Liver Disease</i> , 2006, 38, S149.	0.4	1
286	Reply to K. Rostami et al.. <i>Endoscopy</i> , 2007, 39, 574-574.	1.0	1
287	Accuracy and Learning Curve and of the Water-Immersion Technique in Assessing Marked Villous Atrophy of the Duodenum: A Single Centre 4-Year Experience. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB339.	0.5	1
288	PO.13 RIFAXIMIN VERSUS METRONIDAZOLE FOR THE TREATMENT OF SMALL BOWEL BACTERIAL OVERGROWTH. <i>Digestive and Liver Disease</i> , 2008, 40, S175.	0.4	1

#	ARTICLE	IF	CITATIONS
289	Patchy Left-Sided Colitis: Primary Eosinophilic Colitis or Paraneoplastic Syndrome?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, e61.	2.4	1
290	OC.05.5 DEVELOPMENT AND VALIDATION OF AN ENDOSCOPIC CLASSIFICATION OF DIVERTICULAR DISEASE OF THE COLON: THE DICA CLASSIFICATION. <i>Digestive and Liver Disease</i> , 2014, 46, S14-S15.	0.4	1
291	P090 Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S99-S100.	0.6	1
292	P.17.13 WHITE MULBERRY SUPPLEMENTATION AS ADJUVANT TREATMENT OF OBESITY. <i>Digestive and Liver Disease</i> , 2014, 46, S124.	0.4	1
293	Olmesartan-associated sprue-like enteropathy: know your enemy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 891-891.	0.6	1
294	Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium" <i>Circulation</i> , 2018, 137, 213-214.	1.6	1
295	Gut microbiome beats two to zero host genome. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 378-380.	0.7	1
296	<i>Helicobacter pylori</i> and gastro-oesophageal reflux disease: Information on underlying pathology is not given. <i>BMJ: British Medical Journal</i> , 2004, 329, 402.1.	2.4	1
297	Eradication of <i>Helicobacter pylori</i> in routine clinical practice: doubts and uncertainties. <i>Hepato-Gastroenterology</i> , 1999, 46, 312-5.	0.5	1
298	Minimal endoscopic aspects of gastric low-grade malt-lymphoma. <i>Hepato-Gastroenterology</i> , 1999, 46, 2818-22.	0.5	1
299	Regression of E12-stage low-grade gastric MALT-lymphoma after H. pylori eradication. <i>Hepato-Gastroenterology</i> , 2005, 52, 975-7.	0.5	1
300	Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 5826-5835.	0.5	1
301	The Italian National Faecal Microbiota Transplantation Program: a coordinated effort against <i>Clostridioides difficile</i> infection. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2021, 57, 239-243.	0.2	1
302	<i>Helicobacter pylori</i> and the Anatomoclinical Spectrum of Duodenal Ulcer Disease. <i>Journal of Clinical Gastroenterology</i> , 1994, 18, 239.	1.1	0
303	Effect of anti- <i>Helicobacter pylori</i> therapy on inflammatory cell infiltration and acquired malt in gastric mucosa: A morphometric study by means of computer-assisted image analysis. <i>Gastroenterology</i> , 1995, 108, A48.	0.6	0
304	Disappearance of gastric acquired malt and regression of low-grade B-cell gastric lymphoma by means anti-H. pylori treatment. <i>Gastroenterology</i> , 1995, 108, A65.	0.6	0
305	1.P.303 A new human atrial natriuretic peptide gene C/T polymorphism is more frequent in type 1 microalbuminuric diabetic patients. <i>Atherosclerosis</i> , 1997, 134, 81.	0.4	0
306	<i>Helicobacter pylori</i> infection and idiopathic arrhythmias. <i>Gastroenterology</i> , 1998, 114, A123.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Role of Helicobacter pylori infection in dyspepsia. Gastroenterology, 1998, 114, A130.	0.6	0
308	Is there any relationship between IEL and lymphoid follicles in the gastric mucosa? Reply. Gut, 2000, 47, 314-315.	6.1	0
309	Factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Gastroenterology, 2000, 118, A1363.	0.6	0
310	Relationship between gastric localization of HCV and gastric, H. pylori-related lymphoid tissue. Journal of Hepatology, 2001, 34, 130.	1.8	0
311	Relationship between gastric localization of hepatitis C virus and gastric mucosa-associated lymphoid tissue related to Helicobacter pylori infection. Gastroenterology, 2001, 120, A746-A747.	0.6	0
312	First-line treatment for Helicobacter pylori eradication: New moxifloxacin-based strategies. Gastroenterology, 2003, 124, A359.	0.6	0
313	Impact of bacillus clausii supplementation on anti Helicobacter pylori therapy related side effects: A randomized double blind placebo controlled study. Gastroenterology, 2003, 124, A361.	0.6	0
314	Increased prevalence of small intestinal bacterial overgrowth in patients with non-erosive reflux disease (NERD). Digestive and Liver Disease, 2006, 38, S81.	0.4	0
315	Fecal calprotectini in first degree relatives of patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 669.	0.9	0
316	Role of the Fujinon Intelligent Chromo Endoscopy (FICE) for Detection of Patients with Suspected Celiac Disease (CD): A Pilot Study. Gastrointestinal Endoscopy, 2007, 65, AB356.	0.5	0
317	OC3.08.2 SMALL INTESTINAL BACTERIAL OVERGROWTH IN A CHILDREN POPULATION AFFECTED BY IRRITABLE BOWEL SYNDROME: A CASE-CONTROL STUDY. Digestive and Liver Disease, 2008, 40, S59.	0.4	0
318	OC3.09.2 EFFECT OF LACTOSE AMOUNT PRESENT IN DRUGS ON H2 EXCRETION AND GASTROINTESTINAL SYMPTOMS. Digestive and Liver Disease, 2008, 40, S62-S63.	0.4	0
319	PA.10 ROLE OF VIRTUAL CHROMO-ENDOSCOPY (CVC) FOR DETECTION OF PATIENTS WITH COMPLICATED GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD): APILOTSTUDY. Digestive and Liver Disease, 2008, 40, S79.	0.4	0
320	PA.29 IMPACT OF L. REUTERII SUPPLEMENTATION ON ANTI-H. PYLORI SECOND LINE THERAPY-RELATED. Digestive and Liver Disease, 2008, 40, S86.	0.4	0
321	PA.49 LACTOSE MALABSORPTION IN PATIENTS AFFECTED BY RECURRENT VAGINITIS. Digestive and Liver Disease, 2008, 40, S93.	0.4	0
322	PA.53 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IN PATIENTS WITH DUODENOGASTRIC REFLUX (DGR) POST-CHOLECYSTECTOMY. Digestive and Liver Disease, 2008, 40, S94-S95.	0.4	0
323	PA.55 SMALL INTESTINAL BACTERIAL OVERGROWTH RECURRENCE AFTER ANTIBIOTIC THERAPY. Digestive and Liver Disease, 2008, 40, S95.	0.4	0
324	PA.58 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) CAN AFFECT INTESTINAL PERMEABILITY. Digestive and Liver Disease, 2008, 40, S96.	0.4	0

#	ARTICLE	IF	CITATIONS
325	PA.194 VALUE OF THE WATER-IMMERSION TECHNIQUE DURING UPPER ENDOSCOPY IN EVALUATING DUODENAL VILLOUS ATROPHY IN CELIAC CHILDREN. <i>Digestive and Liver Disease</i> , 2008, 40, S146-S147.	0.4	0
326	PA.248 MAGNIFICATION WITH VIRTUAL CHROMO-ENDOSCOPY (CVC) IN THE EVALUATION OF COLORECTAL MUCOSAL LESIONS: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2008, 40, S166.	0.4	0
327	Reply to Souza et al.. <i>Endoscopy</i> , 2008, 40, 621-621.	1.0	0
328	CYCLIC TREATMENT WITH MESALAZINE IN PREVENTING RECURRENCE OF SMALL INTESTINAL BACTERIAL OVERGROWTH AFTER ANTIBIOTIC TREATMENT. <i>Digestive and Liver Disease</i> , 2009, 41, S67.	0.4	0
329	OC.06.3 METABOLIC SYNDROME PROMOTES THE OCCURRENCE OF PRE-NEOPASTIC LESIONS OF THE COLONIC MUCOSA. <i>Digestive and Liver Disease</i> , 2010, 42, S84.	0.4	0
330	OC.09.1 DYNAMICS OF INTESTINAL REGENERATION FOLLOWING GLUTEN-FREE DIET IN CELIAC PATIENTS AND ROLE OF CIRCULATING HEMATOPOIETIC STEM CELLS. <i>Digestive and Liver Disease</i> , 2010, 42, S91.	0.4	0
331	I-Scan Technology is Useful to Improve the Rate of Gastric Varices Diagnosis in Patients With Portal Hypertension. <i>Gastroenterology</i> , 2011, 140, S-753.	0.6	0
332	P.1.38: SEQUENTIAL AND STANDARD LEVOFLOXACIN-BASED H. PYLORI ERADICATING REGIMENS COMPARED TO QUADRUPLE THERAPY: EFFECT OF LEVOFLOXACIN DOSAGE AND WAY OF ADMINISTRATION. <i>Digestive and Liver Disease</i> , 2011, 43, S160-S161.	0.4	0
333	P.1.57: LGR5+ INTESTINAL STEM CELLS INVOLVEMENT IN EPITHELIAL REGENERATION FOLLOWING GLUTEN FREE DIET IN CELIAC PATIENTS. <i>Digestive and Liver Disease</i> , 2011, 43, S167.	0.4	0
334	P.1.303: HIGH DOSE AMOXICILLIN-BASED FIRST LINE REGIMEN IS EQUIVALENT TO SEQUENTIAL THERAPY IN THE ERADICATION OF H. PYLORI INFECTION. <i>Digestive and Liver Disease</i> , 2011, 43, S248-S249.	0.4	0
335	Gastrointestinal: An unusual gastric flat lesion: amyloidosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 784-784.	1.4	0
336	OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS. <i>Digestive and Liver Disease</i> , 2014, 46, S26-S27.	0.4	0
337	OC.13.4 MULTIPARAMETRIC EVALUATION OF CROHN'S DISEASE: INTESTINAL HEALING BEYOND MUCOSAL HEALING. <i>Digestive and Liver Disease</i> , 2014, 46, S31.	0.4	0
338	P182 Multiparametric evaluation of Crohn's disease: possible role of intestinal healing beyond mucosal healing. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S138.	0.6	0
339	OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION. <i>Digestive and Liver Disease</i> , 2014, 46, S35.	0.4	0
340	P184 Mucosal healing does not correspond to histological healing in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S139.	0.6	0
341	P.18.4 EFFICACY OF ANTIOXIDANT THERAPY IN IMPROVING PAINFUL CHRONIC PANCREATITIS: A SYSTEMATIC REVIEW. <i>Digestive and Liver Disease</i> , 2014, 46, S128.	0.4	0
342	P.15.1 PROSPECTIVE VALIDATION OF ENDOFASTER FOR A REALTIME DIAGNOSIS OF H. PYLORI INFECTION DURING UPPER ENDOSCOPY. <i>Digestive and Liver Disease</i> , 2014, 46, S111.	0.4	0

#	ARTICLE	IF	CITATIONS
343	P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE. Digestive and Liver Disease, 2014, 46, S73.	0.4	0
344	Tu1533 Esophageal Posterior and Right Wall Are the Most Common Localizations of Barrett's Esophagus. Gastrointestinal Endoscopy, 2015, 81, AB499.	0.5	0
345	P.12.2 DIAGNOSIS OF CELIAC DISEASE IN ADULTS WITHOUT DUODENAL BIOPSY IN THE PRESENCE OF POSITIVE ANTI-ENDOMYSIUM ANTIBODIES AND ANTI-TRANSGLUTAMINASE ANTIBODIES. Digestive and Liver Disease, 2016, 48, e185.	0.4	0
346	Endoscopic evaluation of celiac disease. Endoscopy International Open, 2016, 04, E547-E548.	0.9	0
347	P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?. Digestive and Liver Disease, 2016, 48, e157.	0.4	0
348	P.08.11 THE POSITION WITHIN THE OESOPHAGEAL CIRCUMFERENCE PREDICTS DYSPLASIA IN SHORT SEGMENT BARRETT'S ESOPHAGUS: A 7-YEAR RETROSPECTIVE SERIES OF 341 LESIONS. Digestive and Liver Disease, 2016, 48, e168-e169.	0.4	0
349	OC.12.9 FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT C. DIFFICILE INFECTION: A 2-YEAR EXPERIENCE FROM A EUROPEAN REFERRAL CENTRE. Digestive and Liver Disease, 2016, 48, e118.	0.4	0
350	P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?. Digestive and Liver Disease, 2017, 49, e159.	0.4	0
351	P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis. Digestive and Liver Disease, 2017, 49, e158-e159.	0.4	0
352	Prevention and treatment of Clostridium difficile infection. Geriatric Care, 2017, 3, .	0.2	0
353	OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE. Digestive and Liver Disease, 2019, 51, e90.	0.4	0
354	Letter: improvement of clinical outcomes by metformin in metabolic liver diseaseâ€”a microbiotaâ€”dependent mechanism?. Alimentary Pharmacology and Therapeutics, 2019, 50, 474-474.	1.9	0
355	OC.11.4 CHARACTERIZATION OF ESOPHAGEAL MICROBIOTA IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA. Digestive and Liver Disease, 2019, 51, e107.	0.4	0
356	OC.03.4 DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. Digestive and Liver Disease, 2019, 51, e84-e85.	0.4	0
357	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. Digestive and Liver Disease, 2021, 53, 1527-1528.	0.4	0
358	Residual Gastrointestinal Symptoms after Fecal Microbiota Transplantation for Clostridioides difficile Infection: A Matter of Efficacy Rather Than Safety?. Gastroenterology, 2021, 161, 1344.	0.6	0
359	Benign and malignant laryngeal lesions in patients with different type of surgical resection of the stomach. Gastroenterology, 2001, 120, A423-A423.	0.6	0
360	Fecal Microbiota Transplantation in Children. , 2022, , 709-712.		0

#	ARTICLE	IF	CITATIONS
361	Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure <i>Helicobacter pylori</i> infection. <i>Hepato-Gastroenterology</i> , 2000, 47, 1176-9.	0.5	0
362	<i>Rummeliibacillus suwonensis</i> : First Time Isolation from Human Feces by Culturomics. <i>Current Microbiology</i> , 2022, 79, .	1.0	0